Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

Exclusion Criteria

• •1. Female patients during pregnancy or lactation.
• •2. Diagnosis of bilateral breast cancer, occult breast cancer, or distant metastasis confirmed by pathology.
• •3. Has an active autoimmune disease that has received systemic treatment in the last 2 years.
• •4. Has a known history of human immunodeficiency virus (HIV), hepatitis B, or known active hepatitis C virus infection.
• •5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
• •6. Has a known history of invasive malignancy that required systemic treatment in the last 5 years.
• •7. Uncontrolled concomitant diseases include severe infection, liver disease, cardiovascular disease, kidney disease, respiratory disease, diabetes, and others requiring systemic treatment.